| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0718684.4AGB0718684D0 (en) | 2007-09-24 | 2007-09-24 | Treatment method |
| EP08804245AEP2197916A1 (en) | 2007-09-24 | 2008-09-16 | Fixed single injection dosage for ocrelizumab (2h7) |
| JP2010526246AJP2011501734A (en) | 2007-09-24 | 2008-09-16 | Single fixed infusion dose of ocrelizumab (2H7) |
| PCT/EP2008/062286WO2009040268A1 (en) | 2007-09-24 | 2008-09-16 | Fixed single injection dosage for ocrelizumab (2h7) |
| CN200880108541ACN101809036A (en) | 2007-09-24 | 2008-09-16 | Fixed single injection dosage for ocrelizumab (2H7) |
| CA2700351ACA2700351A1 (en) | 2007-09-24 | 2008-09-16 | Fixed single injection dosage for ocrelizumab (2h7) |
| ARP080104116AAR068531A1 (en) | 2007-09-24 | 2008-09-22 | FIXED DOSE BY ONE INJECTION FOR OCRELIZUMAB (2H7). USE OF RITUXIMAB. PHARMACEUTICAL FORMULATION KIT |
| CL2008002817ACL2008002817A1 (en) | 2007-09-24 | 2008-09-22 | Use of a cd20 antagonist, preferably an antibody, to prepare a medicament against autoimmune diseases, preferably rheumatoid arthritis; composition and kit containing it. |
| PE2008001653APE20091078A1 (en) | 2007-09-24 | 2008-09-22 | INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7) |
| TW097136506ATW200918091A (en) | 2007-09-24 | 2008-09-23 | Fixed single injection dosage for ocrelizumab (2H7) |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0718684.4AGB0718684D0 (en) | 2007-09-24 | 2007-09-24 | Treatment method |
| Publication Number | Publication Date |
|---|---|
| GB0718684D0true GB0718684D0 (en) | 2007-10-31 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0718684.4ACeasedGB0718684D0 (en) | 2007-09-24 | 2007-09-24 | Treatment method |
| Country | Link |
|---|---|
| EP (1) | EP2197916A1 (en) |
| JP (1) | JP2011501734A (en) |
| CN (1) | CN101809036A (en) |
| AR (1) | AR068531A1 (en) |
| CA (1) | CA2700351A1 (en) |
| CL (1) | CL2008002817A1 (en) |
| GB (1) | GB0718684D0 (en) |
| PE (1) | PE20091078A1 (en) |
| TW (1) | TW200918091A (en) |
| WO (1) | WO2009040268A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026470D1 (en) | 2003-11-05 | 2010-05-20 | Roche Glycart Ag | FC RECEPTOR AND EFFECTOR FUNCTION |
| TW201438738A (en) | 2008-09-16 | 2014-10-16 | Genentech Inc | Method for treating progressive multiple sclerosis |
| WO2017062682A2 (en)* | 2015-10-06 | 2017-04-13 | Genentech, Inc. | Method for treating multiple sclerosis |
| JP7166925B2 (en)* | 2016-03-07 | 2022-11-08 | サノフィ・バイオテクノロジー | Compositions and methods for treating rheumatoid arthritis |
| MA49830A (en)* | 2017-08-08 | 2021-03-31 | Hoffmann La Roche | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
| EP3856246A4 (en)* | 2018-09-24 | 2022-07-20 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| JP2023507053A (en)* | 2019-10-12 | 2023-02-21 | バイオ－セラ ソリューションズ リミテッド | Anti-CD20 Antibody Preparations and Use of Anti-CD20 Antibodies for Treatment of CD20-Positive Diseases |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2301966A1 (en)* | 2002-12-16 | 2011-03-30 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2006076651A2 (en)* | 2005-01-13 | 2006-07-20 | Genentech, Inc. | Treatment method |
| EP1919505A2 (en)* | 2005-07-25 | 2008-05-14 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
| MY149159A (en)* | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| Publication number | Publication date |
|---|---|
| TW200918091A (en) | 2009-05-01 |
| JP2011501734A (en) | 2011-01-13 |
| CL2008002817A1 (en) | 2009-10-16 |
| EP2197916A1 (en) | 2010-06-23 |
| CA2700351A1 (en) | 2009-04-02 |
| PE20091078A1 (en) | 2009-07-23 |
| WO2009040268A1 (en) | 2009-04-02 |
| AR068531A1 (en) | 2009-11-18 |
| CN101809036A (en) | 2010-08-18 |
| Publication | Publication Date | Title |
|---|---|---|
| IL212348A0 (en) | Treatment method | |
| GB0714363D0 (en) | Treatment apparatus | |
| IL213619A0 (en) | Treatment | |
| GB0707096D0 (en) | Method | |
| GB0802116D0 (en) | Treatment | |
| EP2171169A4 (en) | Method | |
| GB0822011D0 (en) | Treatment | |
| GB0711342D0 (en) | Well treatment | |
| IL238394A0 (en) | Cancer treatment method | |
| GB0811992D0 (en) | Treatment | |
| GB0703366D0 (en) | Method | |
| GB0718684D0 (en) | Treatment method | |
| GB0710321D0 (en) | Method | |
| GB0708960D0 (en) | Method | |
| EP2182884A4 (en) | Treatment apparatus | |
| GB0716784D0 (en) | Well treatment | |
| GB0705321D0 (en) | Method | |
| GB0820972D0 (en) | Treatment | |
| GB0805912D0 (en) | Treatment | |
| GB0706833D0 (en) | Method | |
| EP2203432A4 (en) | Method of treatment | |
| GB0710398D0 (en) | Method | |
| GB0711228D0 (en) | Treatment method | |
| ZA201102198B (en) | Treatment method | |
| GB0715307D0 (en) | Therapeutic method |
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |